SIGLEC7 and cancer: To deeply understand Siglec‐7 binding to closely related sialoglycan structures, and with the long‐term goal of developing potential ligands within cancer immunotherapy, we undertook a comprehensive study of Siglec‐7 recognition and binding to the sugar portions of GD3[22] and two Gb3 (globotriaosylceramide) derivatives,[23] such as DSGb3α3 and DSGb3α6 (Scheme S1, Supporting Information).